Undisclosed Oncology Program(s)

About Cell BioEngines

Cell BioEngines is an emerging player in the allogeneic cell therapy space, leveraging a proprietary 'super-donor' stem cell platform to create transgene-free, scalable therapies. Its strategy combines HLA-guided design with a population-informed biobank to achieve broad patient coverage across multiple diseases. The company operates with a therapeutic area-agnostic, portfolio-focused business model aimed at reducing development time, translational costs, and overall risk.

About miRecule

miRecule is an emerging biotechnology company focused on the discovery and development of precision RNA therapeutics for oncology and neuromuscular disorders. Its core strategy involves analyzing patient genomic data to inform the design of targeted RNA-based drugs, aiming to address unmet medical needs with a personalized medicine approach. As a newly founded, private company, it is in the pre-clinical or early research stage, positioning itself in the competitive but high-potential fields of RNA and gene therapy. The company's success will hinge on validating its platform and advancing its initial pipeline candidates.

About Florica Therapeutics

Florica Therapeutics is a private, pre-clinical stage biotech targeting oncology through the modulation of protein-protein interactions with small molecules. Its core platform is centered on discovering and developing oral therapeutics against intracellular PPIs, a challenging but high-potential target class. As a young company, it is likely in the platform validation and early asset discovery phase, operating with a lean team in the biotech hub of Cambridge. Success hinges on demonstrating proof-of-concept for its platform and advancing a lead candidate into clinical development.

About Base4

Base4 Biotechnology is a private, preclinical-stage company pioneering a structure-based approach to discover small molecules that target RNA, a challenging but high-potential therapeutic modality. Its core asset is the VERITAS Platform, an AI and quantum biophysics-enhanced platform designed to resolve the dynamic atomic structures of RNA and identify druggable sites. Led by a seasoned team with prior biotech founding and exit success, the company is advancing internal programs while seeking strategic partnerships to accelerate drug development in neurodegenerative diseases, oncology, and rare conditions.

About ATB therapeutics

ATB Therapeutics is a private, pre-clinical stage biotech developing a proprietary platform for targeted antibody-based therapies. Its core technology aims to create highly specific biologics for infectious diseases and cancer, potentially offering improved efficacy and reduced side effects. The company is at an early stage, advancing its internal pipeline while seeking strategic partnerships. Its success hinges on validating its platform in the clinic and navigating the competitive landscape of targeted biologics.

About Ziphius Vaccines

Ziphius Vaccines is an emerging biotech developing a proprietary self-amplifying RNA (saRNA) platform coupled with in-house lipid nanoparticle (LNP) delivery systems. The company leverages this technology to create a pipeline targeting infectious diseases, rare diseases, and oncology, aiming for potent, durable effects at lower doses than conventional mRNA. As a private, pre-clinical stage company, Ziphius is building its scientific team and platform capabilities to position itself in the competitive next-generation RNA therapeutics space.

About Cairn Biosciences

Cairn Biosciences, founded in 2018, is a private, preclinical-stage biotech based in San Francisco pioneering a new drug discovery paradigm. The company's core asset is the COMPASS platform, which integrates computational modeling, disease biology, and experimental data to simulate cellular dynamics and uncover novel therapeutic interventions. Cairn is leveraging this platform to address the significant unmet need of acquired resistance in oncology, aiming to deliver first-in-class therapeutics. The company is led by an experienced team with a track record in oncology drug discovery and novel technology development.

About Akelos

Akelos is an early-stage biotech tackling the difficult challenge of inhibiting protein-protein interactions with small molecules, a field with high potential but significant technical hurdles. The company's platform is likely centered on structure-based drug design and screening technologies to identify and optimize compounds for oncology indications. As a private, pre-clinical, and pre-revenue entity, its success hinges on validating its platform through lead optimization and advancing its first programs into clinical trials to attract further partnership and investment.

About Salubris Biotherapeutics

Salubris Biotherapeutics is a private, clinical-stage biotech founded in 2015 and headquartered in Gaithersburg, Maryland. The company is developing novel antibody-based therapeutics targeting the two leading global causes of death: cardiovascular disease and cancer. Led by a seasoned team of industry veterans, SalubrisBio leverages its expertise in complex biologics to advance its pipeline through clinical development. The company is currently pre-revenue and focused on progressing its research programs.

About Kesmalea Therapeutics

Kesmalea Therapeutics is a private, preclinical-stage biotech leveraging its innovative SELFTAC® platform to create a new class of oral, CNS-penetrant protein degraders. The company aims to solve the 'size problem' associated with traditional bifunctional degraders by designing small molecules that self-assemble into active degraders in situ. Backed by a £25 million Series A round co-led by Syncona and Oxford Science Enterprise, Kesmalea is building a pipeline in oncology and CNS with a seasoned leadership team. The company's approach could significantly expand the clinical applicability of targeted protein degradation.

Therapeutic Areas

Other Cancer Drugs